Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 2, 2016, Pages 362-366

  Delicado, Teresa Llácer ^a,b,c   Torrecilla, Esther ^a,b,c   Holguín, áfrica ^a,b,c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; RALTEGRAVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE; INTEGRASE INHIBITOR; QUINOLONE DERIVATIVE;

ARTICLE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; SEQUENCE ANALYSIS; VIRUS RESISTANCE; VIRUS TYPING; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; BIOLOGY; ENZYMOLOGY; GENETIC VARIATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; VIROLOGY;

AMINO ACID SUBSTITUTION; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; QUINOLONES; RALTEGRAVIR POTASSIUM;

EID: 84959904913     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv333     Document Type: Article

References (22)

1. Menéndez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 2013; 98: 93-120.
2. Sharma A, Slaughter A, Jena N et al. A new class of multimerization selective inhibitors of HIV-1 integrase. PLoS Pathog 2014; 10: e1004171.
3. Pollicita M, Surdo M, Di Santo F et al. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. J Antimicrob Chemother 2014; 69: 2412-9.
4. Turriziani O, Montagna C, Falasca F et al. Short communication: analysis of the integrase gene fromHIV type 1-positive patients living in a rural area of West Cameroon. AIDS Res Hum Retroviruses 2012; 28: 1729-33.
5. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12: 563-70.
6. Reigadas S, Marcelin AG, Houssaïni A et al. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and-experienced patients with different HIV-1 subtypes. J Antimicrob Chemother 2013; 68: 969-72.
7. Myers RE, Pillay D. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol 2008; 82: 9228-35.
8. Parczewski M, Bander D, Urbańska A et al. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from northwestern Poland. BMC Infect Dis 2012; 12: 368.
9. Bessong PO, Nwobegahay J. Genetic analysis of HIV-1 integrase sequences from treatment naive individuals in northeastern South Africa. Int J Mol Sci 2013; 14: 5013-24.
10. Oliveira MF, Ramalho DB, Abreu CM et al. Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors. AIDS Res Hum Retroviruses 2012; 28: 1788-92.
11. Vavro C, Hasan S, Madsen H et al. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother 2013; 57: 1379-84.
12. Gutiérrez C, Hernández-Novoa B, Pérez-Elías MJ et al. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and-experienced patients infected with B and non-B HIV-1 variants. HIV Clin Trials 2013; 14: 10-6.
13. Cavaco-Silva J, Abecasis A, Miranda AC et al. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. PLoS One 2014; 9: e92747.
14. Bellecave P, Malato L, Calmels C et al. In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir. Int J Antimicrob Agents 2014; 44: 168-72.
15. Malet I, Fourati S, Charpentier C et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 2011; 66: 2827-30.
16. Carganico A, Dupke S, Ehret R et al. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS Soc 2014; 17: 19749.
17. Munir S, Thierry E, Malet I et al. G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. J Antimicrob Chemotherapy 2014; 70: 739-49.
18. Quashie PK, Oliviera M, Veres T et al. Differential effects of the G118R, H51Y and E138K resistance substitutions in different subtypes of HIV integrase. J Virol 2015; 89: 3163-75.
19. Maïga AI, Malet I, Soulie C et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther 2009; 14: 123-9.
20. Martinez-Cajas JL, Pai NP, Klein MB et al. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009; 12: 11.
21. Wares M, Mesplède T, Quashie PK et al. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 2014; 11: 7.
22. Doyle T, Dunn DT, Ceccherini-Silberstein F et al. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV clades. J Antimicrob Chemother 2015; 70: 3080-6.